CD86 and acute myeloid leukemia: Compared to DAC treated only and SZU-106 conjugated only vaccines, the SZU-106-DAC-AML vaccine demonstrated the strongest potency to promote the expression of CD83, HLA-II, and CD86, suggesting its strongest potential to initiate immune responses compared to the indicated controls.